Literature DB >> 11850705

Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.

M G Ottolini1, S R Curtis, A Mathews, S R Ottolini, G A Prince.   

Abstract

Respiratory syncytial virus (RSV) is widely recognized as a leading cause of pneumonia, with substantial mortality, in bone marrow transplant recipients. We tested the efficacy of a systemic monoclonal antibody (MAB) preparation possessing a high titer of anti-RSV neutralizing antibody, palivizumab (Synagis) for prophylaxis and therapy of RSV infection in cytoxan (CY) immunosuppressed cotton rats, a model in which the efficacy of a polyclonal anti-RSV product (Respigam) has been demonstrated. Both prophylaxis and therapy with this MAB were highly effective in reducing pulmonary viral replication. However, multiple sequential therapeutic doses of MAB were necessary to control rebound viral replication in continually suppressed animals.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11850705     DOI： 10.1038/sj.bmt.1703326

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  17 in total

1.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

2.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

3.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

4.  Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement.

Authors:  Sachiko Seo; Angela P Campbell; Hu Xie; Jason W Chien; Wendy M Leisenring; Janet A Englund; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-05       Impact factor: 5.742

5.  The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.

Authors:  Kevin C Yim; Clifford J Carroll; Ana Tuyama; Natalia Cheshenko; Maria Josefina Carlucci; David D Porter; Gregory A Prince; Betsy C Herold
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  In vivo selection of respiratory syncytial viruses resistant to palivizumab.

Authors:  Xiaodong Zhao; Wayne M Sullender
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Respiratory syncytial virus and neutrophil activation.

Authors:  E L Bataki; G S Evans; M L Everard
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

Review 8.  Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.

Authors:  Swapnil Subhash Bawage; Pooja Munnilal Tiwari; Shreekumar Pillai; Vida Dennis; Shree Ram Singh
Journal:  Adv Virol       Date:  2013-12-09

Review 9.  Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation.

Authors:  Brian T Fisher; Sarah Alexander; Christopher C Dvorak; Theoklis E Zaoutis; Danielle M Zerr; Lillian Sung
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

10.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.